Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00149539 · ClinicalTrials.gov registry record · Phase 2
Abuse Potential of Buprenorphine/Naloxone
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00149539 is a Phase 2 study that was terminated before completion, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 12 participants.
The verdict
NCT00149539, a Phase 2 study, was terminated before completion, sponsored by National Institute on Drug Abuse (NIDA).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The purpose of this study is to determine the abuse potential of high doses of buprenorphine/naloxone in opioid dependent individuals.
Interventions
- DRUG Buprenorphine/naloxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00149539
The ClinicalTrials.gov registry entry for NCT00149539 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.
NCT00149539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00149539 about?
NCT00149539 is a clinical study titled "Abuse Potential of Buprenorphine/Naloxone". Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The purpose of this study is to determine the abuse potential of high doses of buprenorphine/naloxone in opioid dep...
What is the current status of trial NCT00149539?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2004-06. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00149539?
The interventions under investigation include: Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT00149539?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.